Purple Biotech Receives Nasdaq Minimum Bid Price Notification
Ticker: PPBT · Form: 6-K · Filed: Oct 20, 2025 · CIK: 1614744
Sentiment: neutral
Topics: listing-compliance, notification, stock-price
TL;DR
Nasdaq says Purple Biotech's stock price is too low, company needs to fix it or get booted.
AI Summary
On October 20, 2025, Purple Biotech Ltd. announced it received a notification from Nasdaq regarding its minimum bid price. The company is working to regain compliance with Nasdaq's listing rules.
Why It Matters
This notification indicates Purple Biotech may be at risk of delisting from the Nasdaq stock exchange if it cannot meet the minimum bid price requirement.
Risk Assessment
Risk Level: medium — Receiving a minimum bid price notification from Nasdaq suggests the company's stock performance is a concern and could lead to delisting.
Key Players & Entities
- Purple Biotech Ltd. (company) — The company filing the report and receiving the notification.
- Nasdaq (company) — The stock exchange that issued the minimum bid price notification.
- October 20, 2025 (date) — The date Purple Biotech announced the notification.
FAQ
What is the specific minimum bid price requirement from Nasdaq?
The filing does not specify the exact minimum bid price requirement, only that Purple Biotech received a notification regarding it.
What actions is Purple Biotech taking to address the minimum bid price issue?
The filing states the company is "working to regain compliance" but does not detail the specific actions being taken.
What is the deadline for Purple Biotech to regain compliance with Nasdaq's minimum bid price rule?
The filing does not mention a specific deadline for regaining compliance.
Has Purple Biotech previously received such a notification from Nasdaq?
This filing does not provide information on whether this is a recurring issue.
What is the current stock price of Purple Biotech?
The filing does not disclose the current stock price of Purple Biotech.
Filing Stats: 192 words · 1 min read · ~1 pages · Grade level 11.5 · Accepted 2025-10-20 16:01:29
Filing Documents
- ea0261818-6k_purple.htm (6-K) — 14KB
- ea026181801ex99-1_purple.htm (EX-99.1) — 16KB
- 0001213900-25-100353.txt ( ) — 31KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. October 20, 2025 PURPLE BIOTECH LTD. By: /s/ Gil Efron Gil Efron Chief Executive Officer 2